FDA Aligns on Pivotal Phase 2 Design for RP-A501 in Danon Disease
RCKT sits 36% above its 52-week low of $2.53.
Summary
Rocket Pharmaceuticals announced FDA alignment on the pivotal Phase 2 trial design for RP-A501 in Danon disease. The FDA confirmed continued enrollment and dosing at a recalibrated dose of 3.8 × 10¹³ GC/kg, with a 12-patient pivotal population and 12-month co-primary endpoints of myocardial LAMP2 protein expression and a 10% reduction in left ventricular mass index. The first three patients treated under the modified protocol count toward the 12-patient total, leaving nine to enroll, with dosing completion expected by mid-2027. This follows the August 3 safety update showing no serious safety issues in the first three patients. The alignment provides a clear regulatory path and supports a potential accelerated approval pathway. A comprehensive program update is scheduled for an investor webinar on October 6, 2026.
At the time of this announcement, RCKT was trading at $3.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $376.5M. The 52-week trading range was $2.53 to $5.45. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.